Ribomic Inc. (4591)

Overview

Ribomic Inc. is a biopharmaceutical company based in Tokyo, Japan, founded in 2003. It specializes in the discovery and development of innovative pharmaceutical compounds by leveraging RNA aptamers. These aptamers are short RNA molecules that have the unique ability to bind specifically to targeted proteins, which makes them highly efficient in therapeutic applications. Ribomic Inc. focuses on addressing a range of diseases, including chronic and serious conditions that lack effective treatments. The company's mission is to harness the potential of RNA aptamers to develop drugs that can significantly improve patient outcomes and quality of life.

Products and Services

Ribomic Inc.'s portfolio includes drugs in various stages of development, targeting diseases such as:

• Wet Age-Related Macular Degeneration: They are developing a novel treatment for this condition, which is a leading cause of blindness in the elderly. The RNA aptamer-based drug aims to inhibit abnormal blood vessel growth in the eye, which is a hallmark of the disease.
• Achondroplasia: The company is working on a therapeutic solution for achondroplasia, the most common form of dwarfism, using RNA aptamers to target and modulate the signaling pathways involved in bone growth.
• Pulmonary Arterial Hypertension: Ribomic Inc. is developing a drug to treat pulmonary arterial hypertension, a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. Their approach involves targeting specific proteins implicated in the disease's pathogenesis to reduce pulmonary artery pressure.
• Proliferative Vitreoretinopathy: The company has a drug candidate for proliferative vitreoretinopathy, a condition that can develop after retinal detachment surgery and often leads to blindness. The treatment aims to prevent the abnormal growth of scar tissues in the eye.
• Heart Failure: A heart failure treatment is in the works, focusing on improving heart function by targeting molecular pathways involved in cardiac muscle contraction and relaxation.
• Osteoarthritis: Ribomic Inc. is developing a treatment for osteoarthritis, aiming to target and relieve the symptoms of this degenerative joint disease, potentially slowing its progression.
• Asthma: The company is also focused on creating a novel therapeutic for asthma, a chronic inflammatory disease of the airways, by targeting molecules involved in the inflammatory response.
• Separating Agents for Affinity Purification of Human IgG and Fc-fusion Proteins: Beyond therapeutics, Ribomic Inc. offers products for the biotechnology industry, including separating agents that are critical in the affinity purification process of human IgG and Fc-fusion proteins. These agents ensure the purity and efficacy of biopharmaceutical products.